Peter K Kaiser1. 1. Cleveland Clinic, Cleveland, OH, USA. pkkaiser@aol.com
Abstract
PURPOSE: To provide an overview of angiogenesis and vascular endothelial growth factor (VEGF) and discusses the development approach, safety, and efficacy results of current and emerging anti-VEGF therapies for ocular diseases. DESIGN: Analysis of literature and current clinical trials of antiangiogenic agents for age-related macular degeneration (AMD). METHODS: Literature review. RESULTS: There are several novel antiangiogenic molecules that target vascular endothelial growth factor and are being used in the management of AMD. Large scale, Phase III trials have shown promising results in improving vision in this devastating disease. CONCLUSIONS: Therapies that target VEGF have shown tremendous promise as treatments for AMD.
PURPOSE: To provide an overview of angiogenesis and vascular endothelial growth factor (VEGF) and discusses the development approach, safety, and efficacy results of current and emerging anti-VEGF therapies for ocular diseases. DESIGN: Analysis of literature and current clinical trials of antiangiogenic agents for age-related macular degeneration (AMD). METHODS: Literature review. RESULTS: There are several novel antiangiogenic molecules that target vascular endothelial growth factor and are being used in the management of AMD. Large scale, Phase III trials have shown promising results in improving vision in this devastating disease. CONCLUSIONS: Therapies that target VEGF have shown tremendous promise as treatments for AMD.